The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Abstract
IGF-I receptor (IGF-IR) signaling and functions are mediated through the activities of a complex molecular network of positive (e.g., type I IGF) and negative (e.g., the type II IGF receptor, IGF-IIR) effectors. Under normal physiological conditions, the balance between the expression and activities of these molecules is tightly controlled. Changes in this delicate balance (e.g., overexpression of one effector) may trigger a cascade of molecular events that can ultimately lead to malignancy. In recent years, evidence has been mounting that the IGF axis may be involved in human cancer progression and can be targeted for therapeutic intervention. Here we review old and more recent evidence on the role the IGF system in malignancy and highlight experimental and clinical studies that provide novel insights into the complex mechanisms that contribute to its oncogenic potential. Controversies arising from conflicting evidence on the relevance of IGF-IR and its ligands to human cancer are discussed. Our review highlights the importance of viewing the IGF axis as a complex multifactorial system and shows that changes in the expression levels of any one component of the axis, in a given malignancy, should be interpreted with caution and viewed in a wider context that takes into account the expression levels, state of activation, accessibility, and functionality of other interacting components. Because IGF targeting for anticancer therapy is rapidly becoming a clinical reality, an understanding of this complexity is timely because it is likely to have an impact on the design, mode of action, and clinical outcomes of newly developed drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
Protein modules and signalling networks
Pawson, T. (1995) · Nature · doi:10.1038/373573a0 · Cited by 2,420
G 1 Events and Regulation of Cell Proliferation
Pardee, A. B. (1989) · Science · doi:10.1126/science.2683075 · Cited by 2,182
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., & Mihatsch, M. J. (2000) · Human Pathology · doi:10.1053/hp.2000.6698 · Cited by 1,895
Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., & Chen, E. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04528.x · Cited by 1,844
GROWTH FACTOR RECEPTOR TYROSINE KINASES
Yarden, Y., & Ullrich, A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002303 · Cited by 1,838
Cited by
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,033
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Adipose tissue and adipocytes support tumorigenesis and metastasis
Nieman, K. M., Romero, I. L., Van Houten, B., & Lengyel, E. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.02.010 · Cited by 749
ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway
Zhao, Y., Hu, X., Liu, Y., Dong, S., Wen, Z., He, W., Zhang, S., Huang, Q., & Shi, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0648-1 · Cited by 735
“These growth factors are increased via autocrine or paracrine signals in nutrient-abundant conditions [56], indicating the role of AKT in proliferation is closely related to a well suitable growth milieu.”
(2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70095-4 · Cited by 652
Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives
Roberts, D. L., Dive, C., & Renehan, A. G. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082713 · Cited by 610
Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms
Arcidiacono, B., Iiritano, S., Nocera, A., Possidente, K., Nevolo, M. T., Ventura, V., Foti, D., Chiefari, E., & Brunetti, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/789174 · Cited by 606
The Role of Liver-Derived Insulin-Like Growth Factor-I
Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, A., Isgaard, J., Isaksson, O., Jansson, J.-O., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 453
The Type 1 Insulin-Like Growth Factor Receptor Pathway
Chitnis, M. M., Yuen, J. S. P., Protheroe, A. S., Pollak, M., & Macaulay, V. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4879 · Cited by 445
Stromal cell diversity associated with immune evasion in human triple‐negative breast cancer
Wu, S. Z., Roden, D. L., Wang, C., Holliday, H., Harvey, K., Cazet, A. S., Murphy, K. J., Pereira, B., Al‐Eryani, G., Bartonicek, N., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019104063 · Cited by 436
Obesity and cancer: Pathophysiological and biological mechanisms
Renehan, A. G., Roberts, D. L., & Dive, C. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801954303 · Cited by 402
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Fontana, L., Weiss, E. P., Villareal, D. T., Klein, S., & Holloszy, J. O. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00417.x · Cited by 393
Graham, T. R., Zhau, H. E., Odero-Marah, V. A., Osunkoya, A. O., Kimbro, K. S., Tighiouart, M., Liu, T., Simons, J. W., & O'Regan, R. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2559 · Cited by 384
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 380
Self-citationInsulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Gene methylation in gastric cancer
Qu, Y., Dang, S., & Hou, P. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.05.002 · Cited by 373
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
The growth hormone receptor: mechanism of activation and clinical implications
Brooks, A. J., & Waters, M. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.123 · Cited by 357
Minireview: IGF, Insulin, and Cancer
Gallagher, E. J., & LeRoith, D. (2011) · Endocrinology · doi:10.1210/en.2011-0231 · Cited by 349
Self-citationModifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
Clemmons, D. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2359 · Cited by 340
Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., Batzel, G. N., Yin, D., Pritchard-Jones, K., Judson, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70354-7 · Cited by 340
Lee, C., Safdie, F. M., Raffaghello, L., Wei, M., Madia, F., Parrella, E., Hwang, D., Cohen, P., Bianchi, G., & Longo, V. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3228 · Cited by 324
Does diabetes therapy influence the risk of cancer?
Smith, U., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1441-5 · Cited by 316
Visceral obesity, metabolic syndrome, insulin resistance and cancer
Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s002966511100320x · Cited by 309
Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
Locatelli, V., & Bianchi, V. E. (2014) · International Journal of Endocrinology · doi:10.1155/2014/235060 · Cited by 307
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301
Self-citationThe Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer
Langer, C. J., Besse, B., Gualberto, A., Brambilla, E., & Soria, J.-C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8126 · Cited by 300
Gualberto, A., & Pollak, M. (2009) · Oncogene · doi:10.1038/onc.2009.172 · Cited by 274
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272
Haluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., Yap, T. A., Roberts, M. L., Sharma, A., Gualberto, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1118 · Cited by 270
Smith, T. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002469 · Cited by 267
Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review
Bergman, D., Halje, M., Nordin, M., & Engström, W. (2013) · Gerontology · doi:10.1159/000343995 · Cited by 260
Visceral adiposity, insulin resistance and cancer risk
Donohoe, C. L., Doyle, S. L., & Reynolds, J. V. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-12 · Cited by 247
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914076107 · Cited by 235
Non-Islet Cell Tumour-Induced Hypoglycaemia: A Review of the Literature Including Two New Cases
de Groot, J. W. B., Rikhof, B., van Doorn, J., Bilo, H. J. G., Alleman, M. A., Honkoop, A. H., & van der Graaf, W. T. A. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0161 · Cited by 222
Haluska, P., Worden, F., Olmos, D., Yin, D., Schteingart, D., Batzel, G. N., Paccagnella, M. L., de Bono, J. S., Gualberto, A., & Hammer, G. D. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1083-9 · Cited by 197
Weinstein, D., Simon, M., Yehezkel, E., Laron, Z., & Werner, H. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.912 · Cited by 179
Almeida, M. Q., Fragoso, M. C. B. V., Lotfi, C. F. P., Santos, M. G., Nishi, M. Y., Costa, M. H. S., Lerario, A. M., Maciel, C. C., Mattos, G. E., Jorge, A. A. L., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0065 · Cited by 176
IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors
Evdokimova, V., Tognon, C. E., Benatar, T., Yang, W., Krutikov, K., Pollak, M., Sorensen, P. H. B., & Seth, A. (2012) · Science Signaling · doi:10.1126/scisignal.2003184 · Cited by 176
Shukla, A., Grisouard, J., Ehemann, V., Hermani, A., Enzmann, H., & Mayer, D. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0240 · Cited by 130
Insulin-like growth factor (IGF) axis in cancerogenesis
Kasprzak, A., Kwasniewski, W., Adamek, A., & Gozdzicka-Jozefiak, A. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.08.007 · Cited by 130
From obesity to cancer: a review on proposed mechanisms
Tahergorabi, Z., Khazaei, M., Moodi, M., & Chamani, E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3229 · Cited by 118
Targeting the insulin growth factor receptor 1
Arnaldez, F. I., & Helman, L. J. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.01.004 · Cited by 88
Child, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1123 · Cited by 58
Runchey, S. S., Pollak, M. N., Valsta, L. M., Coronado, G. D., Schwarz, Y., Breymeyer, K. L., Wang, C., Wang, C.-Y., Lampe, J. W., & Neuhouser, M. L. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.107 · Cited by 56
Cattaneo, E., Laczko, E., Buffoli, F., Zorzi, F., Bianco, M. A., Menigatti, M., Bartosova, Z., Haider, R., Helmchen, B., Sabates‐Bellver, J., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100141 · Cited by 44
Shi, P., Chandra, J., Sun, X., Gergely, M., Cortes, J. E., Garcia‐Manero, G., Arlinghaus, R. B., Lai, R., & Amin, H. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00795.x · Cited by 24
Sacks, D. B. (2012) · Tietz Textbook of Clinical Chemistry and Molecular Diagnostics · doi:10.1016/b978-1-4160-6164-9.00046-9 · Cited by 7
Metadata
- Authors
- Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-02-01
- Volume
- 28
- Issue
- 1
- Pages
- 20-47
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2051839343
- Cited by
- 1,005
- References
- 260
- FWCI
- 54.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.